<div id="readability-page-1"><p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $9.38 and last traded at $9.1220, with a volume of 440382 shares trading hands. The stock had previously closed at $8.81.</p><div><p><span></span><span>Get <strong>Corvus Pharmaceuticals</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>CRVS has been the subject of a number of analyst reports. Barclays initiated coverage on Corvus Pharmaceuticals in a research note on Monday, October 13th. They issued an &#34;overweight&#34; rating and a $16.00 price target for the company. Mizuho  set a $13.00 price objective on Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $14.25.</p><p><b>View Our Latest Research Report on Corvus Pharmaceuticals</b></p><h2>Corvus Pharmaceuticals Price Performance</h2><p>The firm has a market capitalization of $680.56 million, a PE ratio of -17.09 and a beta of 0.64. The business has a 50-day simple moving average of $7.84 and a 200-day simple moving average of $5.76. </p><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.  On average, research analysts expect that  Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2><p>Several institutional investors have recently bought and sold shares of CRVS. Quarry LP acquired a new position in  Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000.  Jain Global LLC purchased a new stake in shares of  Corvus Pharmaceuticals during the third quarter worth about $204,000.  Brevan Howard Capital Management LP acquired a new position in shares of  Corvus Pharmaceuticals during the third quarter valued at about $113,000.  Bank of America Corp DE boosted its stake in  Corvus Pharmaceuticals by 14.5% in the 3rd quarter. Bank of America Corp DE now owns 151,966 shares of the company's stock worth $1,120,000 after purchasing an additional 19,237 shares in the last quarter.  Finally, Creative Planning purchased a new stake in  Corvus Pharmaceuticals during the 3rd quarter worth approximately $186,000. 46.64% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Corvus Pharmaceuticals</h2> (Get Free Report)<p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Corvus Pharmaceuticals</li><li>What is a penny stock? A comprehensive guide</li><li>Kroger Stock Analysis: Digital Pivot, Dividend Safety &amp; 2026 Growth Plan</li><li>How to Calculate Return on Investment (ROI)</li><li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li><li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li><li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRVS

<p>Corvus Pharmaceuticals (NASDAQ:CRVS) reached a new 52-week high, trading as high as $9.38. Analysts have mixed ratings, with Barclays giving an "overweight" rating and a $16 target, while Weiss Ratings issued a "sell" rating. The stock has a Moderate Buy consensus with a $14.25 target. Institutional investors have been active, with 46.64% ownership. Corvus focuses on immune modulator product candidates for various diseases.</p>

Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month High - Here's What Happened